

**MINUTES OF A REGULAR MEETING
OF THE BOARD OF DIRECTORS OF THE
MASSACHUSETTS LIFE SCIENCES CENTER**

DATE: June 24, 2015
TIME: 2:00 p.m. EST
PLACE: Mack Conference Room, Room #1&2
One Ashburton Place, 21st Floor
Boston, Massachusetts

DIRECTORS PRESENT: Secretary Jay Ash
Dominick Ianno (designee for Secretary Kristen Lepore)
Tom Chmura (designee for Robert Caret, Ph.D.)
Peter Parker

DIRECTORS ABSENT: Edward J. Benz, Jr., M.D.
Adelene Perkins
Lydia Villa-Komaroff, Ph.D.

1. Call to Order

Secretary Jay Ash called the meeting of the Board of Directors (the “Board”) of the Massachusetts Life Sciences Center (the “MLSC”) to order at 2:02 p.m. The meeting, having been duly convened, was ready to proceed with its business.

2. Approval of Board Minutes

The Board then reviewed the minutes of the May 26, 2015 Board meeting. Upon a motions duly made, seconded and unanimously carried, the Board adopted the resolution to approve the minutes.

3. Chairs’ Update

Secretary Jay Ash welcomed those in attendance and offered Dominick Ianno the opportunity to provide brief remarks. Mr. Ianno briefly discussed the interim budget that was passed by the Legislature on June 22, 2015 and expressed the Administration’s support for the life sciences industry. Secretary Ash expressed his interest in hearing about the MLSC’s

successes at the BIO Convention, which he referenced as an example of the collaboration needed throughout the state to attract important industry leaders to Massachusetts. The Secretary reinforced the need to have places available for companies to do business in communities throughout the Commonwealth. He stated that there are many towns outside of the metro-Boston region that have a strong desire to attract life sciences companies, and these towns often possess viable areas for development, and those considerations should be kept in mind as the MLSC follows up with the various companies it met at the BIO Convention.

4. Update: Review of 2015 BIO Convention

Mr. Angus McQuilken, Vice President of Marketing and Communications, provided an update regarding the MLSC's participation in the BIO Convention. He shared the successful turnout at the Massachusetts Pavilion, where staff from the MLSC met with companies from around the world, including companies from Germany, Japan, Scotland, Belgium and France. The conference also included a number of announcements. Attendees were informed that German-based SIRION Biotech and Florida-based Tarogenyx and Xcovery are now doing business in Massachusetts, and the Massachusetts Clinical Innovation Gateway was unveiled at a separate press announcement.

Mr. McQuilken then described several MLSC events at the convention, including panel discussions and networking events. Panel discussions included topics such as research opportunities available on the International Space Station, humanitarian efforts in the biopharma industry, Health IT, and innovation in workforce development. Mr. McQuilken noted that staff from the MLSC participated in an array of forums. During SelectUSA, Mr. Benjamin Bradford, Senior Coordinator of Trade Missions and International Relations, gave a presentation about Massachusetts' life sciences industry for international delegates who were considering relocating

or expanding their companies in the United States. Ms. Beth Nicklas, General Counsel and Vice President of Academic and Workforce Programs, presented at the 12th Annual BIO Community College Program, speaking about the MLSC's role in providing training and career pathways for the next generation of workers.

The Massachusetts Pavilion was a highly popular destination for convention goers. The Chinese delegation paid a special visit to the Pavilion and was introduced by Senator Michael Rodrigues and representatives from WuXiAppTech, a recent company arrival in Massachusetts. The Lifecycle Massachusetts Pavilion Reception was also successful at attracting conference attendees to speak with Massachusetts-based industry leaders.

Mr. McQuilken concluded by sharing the MLSC's intent to continue discussions with numerous companies as a result of the success of the Massachusetts Pavilion at showcasing the Commonwealth's life sciences industry, and expressed his hope for announcements of company expansions.

5. Proposal: Cooperative Research Matching Grants FY '15

Ms. Beth Nicklas presented the fourth round of the Cooperative Research Matching Grant Program. The objective of the program is to provide matching grants that accelerate the translation of treatments and therapies "from the research bench to the bedside." The grants enable collaboration between industry and academic partners, and the grants are matched by industry sponsors. The program also has the benefit of attracting out-of-state companies to invest in Massachusetts-based research.

Ms. Nicklas provided an overview of the 2014-15 round of the program. Grants may total as much as \$500,000 for a 2-year period. Eligible sponsors may be any size company and must

match at least 30% of the MLSC grant in cash. The applicant must provide specific details concerning the product's commercialization potential, including projected timelines. Ms. Nicklas then described the applicant review process, from launch in November 2014 to the Board's Investment Committee decision in June of this year.

David Walt of the MLSC Scientific Advisory Board next spoke in support of the program's value for the state. He described the funding as a mechanism to encourage industry-sponsored, late stage research at Massachusetts-based institutions. He further stated that such opportunities for state-funded research commercialization do not exist anywhere else, making the Cooperative Research Matching Grant Program a unique innovation in Massachusetts. He provided an overview of the six partnerships up for approval, which included: Boston Children's Hospital/Neuroelectrics; the Fraunhofer Center for Manufacturing Innovation; Harvard/BASF; Massachusetts General Hospital/EnBiotix; Massachusetts General Hospital/Arsenal Medical; Massachusetts General Hospital/GlaxoSmithKline. He emphasized the wide variety of diseases and medical concerns addressed by the applicants' research, including sepsis, microbial resistant antibiotics, abdominal hemorrhages, cystic fibrosis, and ALS.

Mr. Peter Parker of the MLSC Board's Investment Committee introduced the proposal to authorize the expenditure of \$1,990,380 for the fourth round of the Cooperative Research Program and to authorize the expenditure of monies for grants in the following amounts:

Boston Children's Hospital	\$448,876
Fraunhofer Institute	\$225,000
Harvard University	\$450,000
Massachusetts General Hospital	\$225,000
Massachusetts General Hospital	\$191,504
Massachusetts General Hospital	\$450,000

After further discussion, the Board reviewed the relevant resolution, and, upon motions duly made, seconded and unanimously carried by all voting Board members, the Board adopted the resolution.

6. Proposal: UP Grant Awards

Ms. Pamela Norton, Vice President of Industry Programs and Relations, provided an overview of the Universal Partnerships (UP) Program. The program enables Massachusetts-based companies to access the best science and technology available by providing the opportunity for collaboration with companies, research institutions and universities from all over the world.

Ms. Norton emphasized that the program fills a funding gap that exists for companies at various stages of development in need of an international partner to further an R&D milestone. She further stated that the UP Program leverages Massachusetts' global position as the leading cluster in life sciences to fuel economic development. Ms. Norton concluded her remarks by illustrating the wide variety of applicants from across the Commonwealth, representing all life science sectors from a dozen cities and towns, and companies of all sizes.

Ms. Tal Dinnar, Manager of International Industry Programs and Business Development, gave an overview of the UP review process and timeline. She described the evaluation criteria, which includes such considerations as the novelty of the proposal, the strength of the science, whether the proposal meets an unmet need, how the project will impact the state as a whole and the qualifications of the applicants, among others.

Ms. Norton summarized the companies and milestones of the three candidates recommended for funding by the Scientific Advisory Board. Barrett Technology, partnering with SenseGraphics of Sweden, intends to develop a haptically-enabled patient-assessment software

for their stroke rehabilitative robotic medical device. CamMED, partnering with Dongguan Xindingyuan Jidian Equipment of China, intends to develop an industrial design for a valve-integrated tubing network for an insulin pump device. Felicitex, partnering with Selvita S.A. of Poland, intends to nominate a clinical lead compound for progression into IND-enabling studies.

After Ms. Norton completed her summary of the recommended awardees, Mr. Peter Parker of the Board's Investment Committee reinforced the strength of the applicants' proposals and introduced the proposal for funding the partnerships in the amounts set forth below:

Barrett Technology Inc.	\$200,000
Cam Med LLC	\$175,000
Felicitex Therapeutics Inc.	\$200,000

After further discussion, the Board reviewed the relevant resolution, and, upon motions duly made, seconded and unanimously carried by all voting Board members, the Board adopted the resolution.

7. Proposal: MLSC FY 16 Operating Budget

Mr. Brad Rosenblum, Chief Financial and Administrative Officer, presented an overview of the MLSC's operating budget. After further discussion, the Board reviewed the relevant resolution, and, upon motions duly made, seconded and unanimously carried by all voting Board members, the Board adopted the resolution allocating a total of \$3,604,750 for the MLSC's operating budget.

8. Update on the MLSC CEO Search

Secretary Ash presented two resolutions regarding the MLSC CEO search. He explained that the executive leadership staff at the MLSC is fully committed to running programs and it is not feasible for one of them to take on the role of an acting CEO. Therefore, he proposed the

appointment of Mike Kennealy, Assistant Secretary for Business Growth in the Executive Office of Housing and Economic Development, as the Acting President and Chief Executive Officer. Secretary Ash further stated that the interim appointment would last approximately four to six weeks until a permanent CEO is selected. After further discussion, the Board reviewed the relevant resolution, and, upon motions duly made, seconded and unanimously carried by all voting Board members, the Board adopted the resolution.

Secretary Ash then proposed the formation of a search committee, composed of three members of the Board, to vet and interview candidates for the position of President and Chief Executive Officer of the MLSC. After further discussion, the Board reviewed the relevant resolution, and, upon motions duly made, seconded and unanimously carried by all voting Board members, the Board adopted the resolution.

9. Adjourn

Secretary Ash, upon motion duly made, seconded and unanimously carried, adjourned the meeting at 3:13 p.m.

List of Materials and Exhibits Used During Meeting:

- Minutes from June 26, 2015 Board meeting – Word Document
- Executive Report – Word Document
- Update: Review of 2015 BIO Convention – PowerPoint Document
- Proposal: Cooperative Research Matching Grants FY 15' – PowerPoint Document
- Motion: Cooperative Research Matching Grants FY 15' – Word Document
- Proposal: UP Grant Awards – PowerPoint Document
- Motion: UP Grant Awards – Word Document